乳腺癌组织中ABCG2和VEGF的表达与化疗敏感性的相关性

探讨分析乳腺癌组织中耐药相关蛋白(ABCG2)、血管内皮生长因子(VEGF)的表达与乳腺癌化疗敏感性的关系。选取60例女性乳腺癌新辅助化疗患者化疗前乳腺癌标本。免疫组织化学SP法检测ABCG2、VEGF蛋白表达情况。60例乳腺癌组织中ABCG2、VEGF阳性表达率分别为63.33%(38/60)和76.67%(46/60)。ABCG2的表达水平与肿块大小、TNM分期和淋巴结转移情况相关(P0.05),与ER无明显相关性(P0.05);VEGF表达水平与ER、TNM分期和淋巴结转移相关(P0.05),与肿块大小无关(P0.05)。ABCG2和VEGF表达水平与化疗情况呈负相关(P0.01)。ABCG2、VEGF的表达水平与乳腺癌化疗敏感性相关,可作为评估乳腺癌新辅助化疗的重要指标。     

Ki67预测乳腺癌新辅助化疗效果的临床研究

目的检测接受新辅助化疗的乳腺癌组织化疗前Ki67(细胞增殖核抗原)的表达,探讨其与新辅助化疗效果的关系。方法接受含蒽环类药物新辅助化疗的乳腺癌患者46例,化疗前空心针穿刺获取标本,免疫组化SP法检测乳腺癌组织中Ki67的表达,利用百分数定量Ki67的表达水平,统计学分析Ki67的表达水平与临床病理特征以及新辅助化疗临床效果的关系。结果在Ki67高表达(25%的癌细胞阳性)和低表达(≤25%的癌细胞阳性)的乳腺癌患者中,两组的临床病理特征相似,Ki67高表达组和低表达组的术前化疗临床缓解率分别为85.0%和46.15%,ki67的表达水平与化疗效果有显著相关性(χ2=9.787,P=0.027)。结论新辅助化疗前乳腺癌组织Ki67的表达水平可作为预测乳腺癌新辅助化疗效果的分子指标。     

TOPOⅡ和P53与乳腺癌新辅助化疗疗效的关系研究

【摘要】〓目的〓本研究旨在检测化疗前乳腺癌组织中TOPOⅡ和P53的表达情况,探讨二者与新辅助化疗疗效之间的关系。方法〓本研究回顾性分析了我院乳腺肿瘤医学部自2011年10月至2015年8月接受以蒽环类为基础新辅助化疗的Ⅱ~Ⅲ期浸润性导管癌患者185例,化疗前用空心针穿刺活检,按常规免疫组化的方法检测TOPOⅡ、P53的表达情况。统计学分析TOPOⅡ、P53的表达水平与患者临床病理特征及与新辅助化疗效果的关系。结果〓TOPOⅡ阳性的患者中达到客观缓解的较表达阴性比例更大(P=0.002),P53阳性的患者中达到临床完全缓解的比例比阴性患者更大(P=0.015),TOPOII及P53均为阳性的患者达到临床完全缓解及客观缓解的比例均较高(P=0.010及P=0.027)。结论〓新辅助化疗前乳腺癌组织中TOPOⅡ和P53的表达水平对新辅助化疗有良好的预测效果。     

新辅助化疗后乳腺癌组织中survivin和Ki-67的表达及意义

目的 探讨CTF方案新辅助化疗后乳腺癌组织survivin和Ki-67的表达及其临床意义.方法 应用免疫组化SABC法检测60例行新辅助化疗和60例未行新辅助化疗的乳腺癌组织中survivin 和Ki-67的表达水平.结果 新辅助化疗组survivin和Ki-67阳性率分别为36.7%和38.3%,明显低于对照组的71.7%和61.7%(均P＜0.05);新辅助化疗组survivin的表达与Ki-67表达呈正相关(r=0.47,P＜0.05).新辅助化疗组总有效率73.3%;化疗后部分缓解者survivin阳性率为18.2%,明显低于无效者的81.3%(P＜0.01);化疗后部分缓解者Ki-67阳性率为47.7%,低于无效者的56.3%(P＞0.05).结论 应用CTF方案新辅助化疗缓解率高,近期疗效明显.CTF化疗药物,可能通过抑制乳腺癌survivin表达而抑制肿瘤的增殖.     

BCSG1基因在乳腺癌新辅助化疗疗效评估中的价值

目的:探讨乳腺癌特异基因（BCSG1）在乳腺癌新辅助化疗疗效评估中的价值。方法:采用免疫组化S P法和荧光定量PCR方法检测36例乳腺癌患者新辅助化疗(CEF方案)前后乳腺癌组织BCSG1的表达，比较化疗前后肿瘤体积的变化情况，分析新辅助化疗前后BCSG1蛋白表达与肿瘤形态学变化的关系。结果:36例乳腺癌患者新辅助化疗后肿瘤体积均有明显缩小（P<0.01），病灶缓解率(CR+PR)为85.6%；新辅助化疗后BCSG1 mRNA表达水平亦明显低于化疗前（P<0.05），BCSG1蛋白高表达率低于新辅助化疗前（P<0.01）。结论:乳腺癌新辅助化疗后BCSG1在分子和蛋白水平表达均明显降低，与新辅助化疗后疗效呈负相关（r=-0.539,P<0.01），提示BCSG1可作为乳腺癌新辅助化疗疗效的预测因子。     

表阿霉素联合多西紫杉醇新辅助化疗治疗三阴乳腺癌的疗效及预后评价

目的探讨三阴乳腺癌(TNBC)与非三阴乳腺癌(non-TNBC)接受表阿霉素联合多西紫杉醇方案(ET方案)的化疗敏感性及预后方面的差别。方法对接受ET新辅助化疗方案治疗的249例乳腺癌患者进行回顾性分析。依据免疫组化雌激素受体(ER)、孕激素受体(PR)、表皮生长因子受体2(HER2)表达水平将乳腺癌分为三阴乳腺癌及非三阴乳腺癌两类,分析三阴与非三阴乳腺患者接受ET新辅助化疗方案后,二者病理疗效及远期生存的差别。结果 249例患者中,54(21.7%)例为三阴乳腺癌,195(78.3%)例为非三阴乳腺癌。三阴乳腺癌的病理完全缓解(pCR)率为25.9%,明显高于非三阴乳腺癌的12.3%(P=0.019)。三阴乳腺癌患者,特别是新辅助化疗后仍有癌残留的患者,其5年无病生存率(DFS)及5年的总生存率(OS)均明显低于非三阴乳腺癌(P值均<0.05)。获得pCR的乳腺癌患者5年的DFS和OS均明显高于化疗后仍有癌残留的患者(P值均<0.05)。获得pCR的三阴乳腺癌与非三阴乳腺癌患者的DFS(P=0.837)及OS(P=0.398)均无统计学差异。结论本研究结果表明,相比于非三阴乳腺癌患者,三阴乳腺癌患者具有更高的病理完全缓解率,但预后却较差。     

乳腺癌中CD44v6与CXCR4 mRNA表达及临床意义

目的:研究乳腺癌组织中细胞表面黏附分子拼接变异体-6(CD44v6)和趋化因子受体4(CXCR4)m RNA的表达,探讨其表达相关性及与临床病理之间的关系。方法:应用q RT-PCR检测60例乳腺癌组织及癌旁正常乳腺组织中CD44v6和CXCR4 m RNA的表达,分析两者表达、相关性及其与临床病理学特征的关系。结果:乳腺癌癌组织CD44v6和CXCR4 m RNA表达水平高于癌旁正常乳腺组织(P0.05);CD44v6和CXCR4的m RNA阳性表达率分别为56.67%(34/60)和61.67%(37/60),均明显高于癌旁正常乳腺组织(P0.01),且两者表达具有正相关性(r=0.399,P0.05);CD44v6与CXCR4 m RNA表达与乳腺癌的临床TNM分期及淋巴结转移有关(P0.01,P0.05),与患者的年龄、肿瘤大小及病理类型无关(P0.05)。结论:CD44v6和CXCR与乳腺癌发展和转移密有关,可作为乳腺癌的重要分子标志物和治疗靶点,联合检测两者的m RNA表达对乳腺癌的临床诊断及预后判断具有一定的指导意义。     

趋化因子配体12/趋化因子受体4轴在三阴性乳腺癌组织中表达及与淋巴结转移关系

目的 探讨趋化因子配体12/趋化因子受体4(CXCL12/CXCR4)轴在三阴性乳腺癌组织中表达及与淋巴结转移关系。方法 选择本院2017年1月～2019年7月病理科获得70份三阴性乳腺癌组织标本及配对癌旁组织,34份三阴性乳腺癌转移淋巴结组织。采用免疫组织化学法检测样本中CXCL12、CXCR4表达情况,分析其与临床病理特征关系。结果 癌组织中CXCL12(+)、CXCR4(+)、CXCL12(+)/CXCR4(+)比例高于癌旁组织,差异有统计学意义(P 0. 05);转移淋巴组织中CXCL12(+)/CXCR4(+)比例高于癌组织,差异有统计学意义(P 0. 05)。相关性分析显示,癌组织中CXCL12与CXCR4表达呈正相关(r=0. 632,P=0. 002)。CXCL12(+)病人淋巴结转移率及Ⅲ～Ⅳ期比例高于CXCL12(-)病人(P 0. 05),CXCR4(+)病人淋巴结转移率及Ⅲ～Ⅳ期比例高于CXCR4(-)(P 0. 05)。结论 CXCL12/CXCR4生物轴表达情况与三阴性乳腺癌淋巴结转移及临床分期密切相关,CXCL12/CXCR4表达可能促进淋巴结转移。     

“三阴”乳腺癌新辅助化疗前后BCSG1基因状况研究

目的 探讨乳腺癌特异基因（BCSG1）在“三阴”性乳腺癌新辅助化疗疗效评估中的价值。方法采用免疫组化S．P法和荧光定量PCR方法检测32例“三阴”性乳腺癌患者新辅助化疗（CEF方案）前后乳腺癌组织BCSG1的表达,比较化疗前后肿瘤体积的变化情况,分析新辅助化疗前后BCSG1蛋白表达与肿瘤形态学变化的关系。结果23例乳腺癌患者新辅助化疗后肿瘤体积均有明显缩小,病灶缓解率（CR＋PR）为84．4％;新辅助化疗后BCSG1mRNA表达水平亦明显低于化疗前（P〈O．05）,BCSG1蛋白高表达率低于新辅助化疗前（P〈0．01）。结论BCSG1分子和蛋白水平在“三阴”性乳腺癌新辅助化疗后均明显降低,与新辅助化疗后疗效呈负相关（r=-0．584,P〈0．01）,提示BCSG1可作为“三阴”乳腺癌新辅助化疗疗效的预测因子。     

杭州健康女性定量骨超声测定原发性骨质疏松

目的 评价杭州健康女性骨超声速度(SOS)值随增龄减少和骨质疏松患病率，建立杭州地区女性骨超声速度值参考数据库。方法 定量超声法测定1208例杭州地区健康女性桡骨远端(RAD)，第3指骨近节(PLX)，第V跖骨(MTR)和胫骨中段(TIB)的超声速度值。结果 RAD、PLX、MTR和TIBSOS峰值(Peak of SOS)均出现在40-45岁，TJB的SOS峰值出现在35—40岁，此后随年龄增长而下降。绝经后妇女在绝经后早期和晚期各有1个SOS快速减少期，前见于桡骨近端，平均年减少率为2．4％，后见于胫骨中段，平均年减少率为1．8％。各部位骨SOS累积减少率随年龄增长而增加，到85岁4部位累积减少为13％-18％。60岁以后骨质疏松性症(OP)检出率为45％-70％，OP检出率以桡骨远端最高，60-70岁平均为67％，第3指骨近端次之约50％，胫骨中段最低为36％；75岁以后分别为70％，65％和45％。结论 全身各部位骨超声速度值到达峰值的年龄不同，峰值也各有差异。绝经后妇女骨超声速度值随年龄增加减少较快，应予激素和补钙治疗，桡骨远端为本地区SOS检测和OP检出的敏感部位。     

Importance of echocardiography in prognosis of surgical outcomes in cholecystitis in elderly patients

The authors propose to use more often echocardiography (EchoCG) in examination of elderly (over 60 years) of age patients with cholecystitis that permits to increase surgical activity to 92.4%. Left ventricular ejection fraction is the most informative. When this fraction is lower than 45% surgery must be recommended on vital indications only. EchoCG was used in 155 patients with cholecystitis, 131 of them were operated. 2 (1.52%) patients died due to acute cardio-vascular insufficiency and pulmonary artery thromboembolism.     

脊髓胶质细胞在小鼠骨癌痛形成中的作用

Objective To evaluate the role of gliocyte in the spinal cord in the development of bone cancer pain (BCP) in mice. Methods Forty male C3H/He mice aged 8-10 weeks weighing 18-22 g were randomly divided into 4 groups ( n = 10 each) : group I sham operation (group S) , group II BCP, group Ⅲ PBS and group IV minocyline (group M) . In group BCP, PBS and M, bone cancer pain was produced by injection of NCTC2472 fibrosarcoma cell suspension (2 x 105 cells) 10 μl into medullary cavity of calcaneus bone, while in group S, PBS solution 10 μl was injected instead of cancer cell suspension. In group PBS and M, PBS 5 μl and minocyline 5 μl (dissolved to 0.2 mmol/L in PBS)_were given IT immediately before cancer cell inoculation once a day for 11 consecutive days respectively. Mechanical pain threshold was measured at 1 d before cancer cell inoculation, and at 0, 3, 5, 7, 9 and 11d after cancer cell inoculation. Cold pain threshold was measured at 3, 7, 9 and 11d after cancer cell inoculation. The animals were killed after measurement of pain threshold and L4-6, segment of spinal cord was removed for determination of GFAP and CD11b expression by Western blot. Results Compared with group S, mechanical pain threshold was significantly increased at 3-11 d after cancer cell inoculation in group BCP and PBS, and at 3 and S d after cancer cell inoculation in group M, and cold pain threshold was significantly increased at 7-11 d after cancer cell inoculation, and expression of CD11b and GFAP was up-regulated in group BCP, PBS and M ( P < 0.05) . Compared with group BCP, mechanical pain threshold was significantly decreased at 3-11 d after cancer cell inoculation, cold pain threshold was significantly decreased at 7-11 d after cancer cell inoculation, and expression of CD11b and GFAP was down-regulated in group M ( P <0.05) . ConclusionThe activiton of gliocyte in the spinal cord is involved in the development of bone cancer pian in mice.     

脊髓胶质细胞在小鼠骨癌痛形成中的作用

Objective To evaluate the role of gliocyte in the spinal cord in the development of bone cancer pain (BCP) in mice. Methods Forty male C3H/He mice aged 8-10 weeks weighing 18-22 g were randomly divided into 4 groups ( n = 10 each) : group I sham operation (group S) , group II BCP, group Ⅲ PBS and group IV minocyline (group M) . In group BCP, PBS and M, bone cancer pain was produced by injection of NCTC2472 fibrosarcoma cell suspension (2 x 105 cells) 10 μl into medullary cavity of calcaneus bone, while in group S, PBS solution 10 μl was injected instead of cancer cell suspension. In group PBS and M, PBS 5 μl and minocyline 5 μl (dissolved to 0.2 mmol/L in PBS)_were given IT immediately before cancer cell inoculation once a day for 11 consecutive days respectively. Mechanical pain threshold was measured at 1 d before cancer cell inoculation, and at 0, 3, 5, 7, 9 and 11d after cancer cell inoculation. Cold pain threshold was measured at 3, 7, 9 and 11d after cancer cell inoculation. The animals were killed after measurement of pain threshold and L4-6, segment of spinal cord was removed for determination of GFAP and CD11b expression by Western blot. Results Compared with group S, mechanical pain threshold was significantly increased at 3-11 d after cancer cell inoculation in group BCP and PBS, and at 3 and S d after cancer cell inoculation in group M, and cold pain threshold was significantly increased at 7-11 d after cancer cell inoculation, and expression of CD11b and GFAP was up-regulated in group BCP, PBS and M ( P < 0.05) . Compared with group BCP, mechanical pain threshold was significantly decreased at 3-11 d after cancer cell inoculation, cold pain threshold was significantly decreased at 7-11 d after cancer cell inoculation, and expression of CD11b and GFAP was down-regulated in group M ( P <0.05) . ConclusionThe activiton of gliocyte in the spinal cord is involved in the development of bone cancer pian in mice.     

脊髓胶质细胞在小鼠骨癌痛形成中的作用

Objective To evaluate the role of gliocyte in the spinal cord in the development of bone cancer pain (BCP) in mice. Methods Forty male C3H/He mice aged 8-10 weeks weighing 18-22 g were randomly divided into 4 groups ( n = 10 each) : group I sham operation (group S) , group II BCP, group Ⅲ PBS and group IV minocyline (group M) . In group BCP, PBS and M, bone cancer pain was produced by injection of NCTC2472 fibrosarcoma cell suspension (2 x 105 cells) 10 μl into medullary cavity of calcaneus bone, while in group S, PBS solution 10 μl was injected instead of cancer cell suspension. In group PBS and M, PBS 5 μl and minocyline 5 μl (dissolved to 0.2 mmol/L in PBS)_were given IT immediately before cancer cell inoculation once a day for 11 consecutive days respectively. Mechanical pain threshold was measured at 1 d before cancer cell inoculation, and at 0, 3, 5, 7, 9 and 11d after cancer cell inoculation. Cold pain threshold was measured at 3, 7, 9 and 11d after cancer cell inoculation. The animals were killed after measurement of pain threshold and L4-6, segment of spinal cord was removed for determination of GFAP and CD11b expression by Western blot. Results Compared with group S, mechanical pain threshold was significantly increased at 3-11 d after cancer cell inoculation in group BCP and PBS, and at 3 and S d after cancer cell inoculation in group M, and cold pain threshold was significantly increased at 7-11 d after cancer cell inoculation, and expression of CD11b and GFAP was up-regulated in group BCP, PBS and M ( P < 0.05) . Compared with group BCP, mechanical pain threshold was significantly decreased at 3-11 d after cancer cell inoculation, cold pain threshold was significantly decreased at 7-11 d after cancer cell inoculation, and expression of CD11b and GFAP was down-regulated in group M ( P <0.05) . ConclusionThe activiton of gliocyte in the spinal cord is involved in the development of bone cancer pian in mice.     

脊髓胶质细胞在小鼠骨癌痛形成中的作用

Objective To evaluate the role of gliocyte in the spinal cord in the development of bone cancer pain (BCP) in mice. Methods Forty male C3H/He mice aged 8-10 weeks weighing 18-22 g were randomly divided into 4 groups ( n = 10 each) : group I sham operation (group S) , group II BCP, group Ⅲ PBS and group IV minocyline (group M) . In group BCP, PBS and M, bone cancer pain was produced by injection of NCTC2472 fibrosarcoma cell suspension (2 x 105 cells) 10 μl into medullary cavity of calcaneus bone, while in group S, PBS solution 10 μl was injected instead of cancer cell suspension. In group PBS and M, PBS 5 μl and minocyline 5 μl (dissolved to 0.2 mmol/L in PBS)_were given IT immediately before cancer cell inoculation once a day for 11 consecutive days respectively. Mechanical pain threshold was measured at 1 d before cancer cell inoculation, and at 0, 3, 5, 7, 9 and 11d after cancer cell inoculation. Cold pain threshold was measured at 3, 7, 9 and 11d after cancer cell inoculation. The animals were killed after measurement of pain threshold and L4-6, segment of spinal cord was removed for determination of GFAP and CD11b expression by Western blot. Results Compared with group S, mechanical pain threshold was significantly increased at 3-11 d after cancer cell inoculation in group BCP and PBS, and at 3 and S d after cancer cell inoculation in group M, and cold pain threshold was significantly increased at 7-11 d after cancer cell inoculation, and expression of CD11b and GFAP was up-regulated in group BCP, PBS and M ( P < 0.05) . Compared with group BCP, mechanical pain threshold was significantly decreased at 3-11 d after cancer cell inoculation, cold pain threshold was significantly decreased at 7-11 d after cancer cell inoculation, and expression of CD11b and GFAP was down-regulated in group M ( P <0.05) . ConclusionThe activiton of gliocyte in the spinal cord is involved in the development of bone cancer pian in mice.     

脊髓胶质细胞在小鼠骨癌痛形成中的作用

目的 评价脊髓胶质细胞在小鼠骨癌痛形成中的作用.方法 健康雄性C3H/He小鼠40只,周龄8～10周,体重18～22 g,随机分为4组(n=10):假手术组(S组)、骨癌痛组(B组)、PBS组(P组)和米诺环素组(M组).S组跟骨骨髓腔内注射PBS 10 μl;余3组跟骨骨髓腔内注射含2×105个骨纤维肉瘤细胞的PBS 10 μl制备骨癌痛模型,于造模前即刻开始PBS组鞘内注射PBS 5μl,M组鞘内注射米诺环素(用PBS溶解为0.2 mmol/L)5μl,1次/d,连续11 d.于造模前1 d、造模后即刻、3、5、7、9、11 d时测定机械痛阈;于造模后3、7、9、11 d机械痛阈测定结束后测定冷痛阈.痛阈测定结束后处死小鼠,取脊髓组织,测定神经胶质纤维酸性蛋白(GFAP)和CD11b的表达水平.结果 与S组比较,B组和P组造模后3-11 d时、M组造模后3、5 d时机械痛阈升高,B组、P组和M组造模后7～11 d时冷痛阈升高,脊髓CD11b和GFAP表达上调(P<0.05).与B组比较,M组造模后3-11 d时机械痛阈降低,造模后7-11 d时冷痛阈降低,脊髓CD11b和GFAP表达下调(P<0.05).结论 脊髓胶质细胞(星形胶质细胞和小胶质细胞)的激活参与了小鼠骨癌痛的形成.     

脊髓胶质细胞在小鼠骨癌痛形成中的作用

Objective To evaluate the role of gliocyte in the spinal cord in the development of bone cancer pain (BCP) in mice. Methods Forty male C3H/He mice aged 8-10 weeks weighing 18-22 g were randomly divided into 4 groups ( n = 10 each) : group I sham operation (group S) , group II BCP, group Ⅲ PBS and group IV minocyline (group M) . In group BCP, PBS and M, bone cancer pain was produced by injection of NCTC2472 fibrosarcoma cell suspension (2 x 105 cells) 10 μl into medullary cavity of calcaneus bone, while in group S, PBS solution 10 μl was injected instead of cancer cell suspension. In group PBS and M, PBS 5 μl and minocyline 5 μl (dissolved to 0.2 mmol/L in PBS)_were given IT immediately before cancer cell inoculation once a day for 11 consecutive days respectively. Mechanical pain threshold was measured at 1 d before cancer cell inoculation, and at 0, 3, 5, 7, 9 and 11d after cancer cell inoculation. Cold pain threshold was measured at 3, 7, 9 and 11d after cancer cell inoculation. The animals were killed after measurement of pain threshold and L4-6, segment of spinal cord was removed for determination of GFAP and CD11b expression by Western blot. Results Compared with group S, mechanical pain threshold was significantly increased at 3-11 d after cancer cell inoculation in group BCP and PBS, and at 3 and S d after cancer cell inoculation in group M, and cold pain threshold was significantly increased at 7-11 d after cancer cell inoculation, and expression of CD11b and GFAP was up-regulated in group BCP, PBS and M ( P < 0.05) . Compared with group BCP, mechanical pain threshold was significantly decreased at 3-11 d after cancer cell inoculation, cold pain threshold was significantly decreased at 7-11 d after cancer cell inoculation, and expression of CD11b and GFAP was down-regulated in group M ( P <0.05) . ConclusionThe activiton of gliocyte in the spinal cord is involved in the development of bone cancer pian in mice.     

脊髓胶质细胞在小鼠骨癌痛形成中的作用

Objective To evaluate the role of gliocyte in the spinal cord in the development of bone cancer pain (BCP) in mice. Methods Forty male C3H/He mice aged 8-10 weeks weighing 18-22 g were randomly divided into 4 groups ( n = 10 each) : group I sham operation (group S) , group II BCP, group Ⅲ PBS and group IV minocyline (group M) . In group BCP, PBS and M, bone cancer pain was produced by injection of NCTC2472 fibrosarcoma cell suspension (2 x 105 cells) 10 μl into medullary cavity of calcaneus bone, while in group S, PBS solution 10 μl was injected instead of cancer cell suspension. In group PBS and M, PBS 5 μl and minocyline 5 μl (dissolved to 0.2 mmol/L in PBS)_were given IT immediately before cancer cell inoculation once a day for 11 consecutive days respectively. Mechanical pain threshold was measured at 1 d before cancer cell inoculation, and at 0, 3, 5, 7, 9 and 11d after cancer cell inoculation. Cold pain threshold was measured at 3, 7, 9 and 11d after cancer cell inoculation. The animals were killed after measurement of pain threshold and L4-6, segment of spinal cord was removed for determination of GFAP and CD11b expression by Western blot. Results Compared with group S, mechanical pain threshold was significantly increased at 3-11 d after cancer cell inoculation in group BCP and PBS, and at 3 and S d after cancer cell inoculation in group M, and cold pain threshold was significantly increased at 7-11 d after cancer cell inoculation, and expression of CD11b and GFAP was up-regulated in group BCP, PBS and M ( P < 0.05) . Compared with group BCP, mechanical pain threshold was significantly decreased at 3-11 d after cancer cell inoculation, cold pain threshold was significantly decreased at 7-11 d after cancer cell inoculation, and expression of CD11b and GFAP was down-regulated in group M ( P <0.05) . ConclusionThe activiton of gliocyte in the spinal cord is involved in the development of bone cancer pian in mice.